Lombard Medical (EVARF) vs. Insulet (PODD) Head to Head Review

Lombard Medical (OTCMKTS:EVARF) and Insulet (NASDAQ:PODD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Earnings & Valuation

This table compares Lombard Medical and Insulet’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lombard Medical $12.17 million 0.02 -$31.03 million N/A N/A
Insulet $563.82 million 10.92 $3.29 million $0.05 2,063.60

Insulet has higher revenue and earnings than Lombard Medical.

Analyst Recommendations

This is a breakdown of current ratings for Lombard Medical and Insulet, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lombard Medical 0 0 0 0 N/A
Insulet 0 2 7 1 2.90

Insulet has a consensus target price of $103.80, indicating a potential upside of 0.60%. Given Insulet’s higher probable upside, analysts plainly believe Insulet is more favorable than Lombard Medical.

Profitability

This table compares Lombard Medical and Insulet’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lombard Medical N/A N/A N/A
Insulet 2.37% 7.25% 1.61%

Volatility & Risk

Lombard Medical has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. Comparatively, Insulet has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500.

Summary

Insulet beats Lombard Medical on 9 of the 10 factors compared between the two stocks.

About Lombard Medical

Lombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, Japan, and internationally. The company's principal product is Aorfix, which is an endovascular stent-graft for the treatment of abdominal aortic aneurysms (AAAs) with angulation at the neck of the aneurysm of up to 90 degrees. Its products also include Altura endovascular stent graft system for the treatment of standard AAA anatomies; Aorflex delivery system for accurate placement of Aorfix in the abdominal aorta; and IntelliFlex LP delivery system that enhances the precision and control of Aorfix deployment and placement. Lombard Medical, Inc. sells its products directly through its direct sales force and distributors to state-or-government-owned hospitals. The company was founded in 2000 and is headquartered in Didcot, the United Kingdom.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of drugs over a specified interval of time, at an administered volume. The company sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors. Insulet Corporation was founded in 2000 and is headquartered in Billerica, Massachusetts.

Receive News & Ratings for Lombard Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lombard Medical and related companies with MarketBeat.com's FREE daily email newsletter.